CSIMarket
 


Revolution Medicines Inc   (RVMD)
Other Ticker:  
 

Cumulative Revolution Medicines Inc 's Leverage Ratio for Trailing Twelve Months Period

RVMD's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

RVMD Leverage Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth 22.9 % 86.6 % 72.82 % 13.71 % 6.77 %
Y / Y Total Liabilities Growth -78.82 % -77.58 % -57.26 % -54.01 % 49.31 %
Leverage Ratio for Trailing Twelve Months Period 0.05 0.09 0.14 0.2 0.23
Total Ranking # 310 # 365 # 466 # 639 # 672
Seq. Equity Growth -10.03 % -2.25 % 38.97 % 0.55 % 36.6 %
Seq. Total Liabilities Growth 1.91 % -46.68 % -9.56 % -56.89 % 7.86 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite net new borrowings of 1.91% Revolution Medicines Inc managed to decrease Leverage Ratio for Trailing Twelve Months Period in III. Quarter to 0.05, below Revolution Medicines Inc 's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry Revolution Medicines Inc achieved the lowest Leverage Ratio for Trailing Twelve Months Period. While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are RVMD's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 1
Sector # 13
S&P 500 # 34


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.23 0.18 0.15
(Sep 30 2022)   (Sep 30 2021)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Ambrx Biopharma Inc   0.14 
Atyr Pharma Inc   0.14 
Springworks Therapeutics Inc   0.14 
Intensity Therapeutics Inc   0.13 
Immunovant Inc   0.12 
Molecular Partners Ag  0.12 
Argenx se  0.11 
Invivyd Inc   0.11 
Athira Pharma Inc   0.11 
Protara Therapeutics Inc   0.10 
4d Molecular Therapeutics Inc   0.10 
Icosavax Inc   0.09 
Revolution Medicines Inc   0.09 
Aim Immunotech Inc   0.08 
Cardiff Oncology inc   0.08 
Compass Therapeutics Inc   0.08 
Achilles Therapeutics Plc  0.07 
Ainos Inc   0.07 
Vigil Neuroscience Inc   0.07 
Creative Medical Technology Holdings Inc   0.07 
Cabaletta Bio Inc   0.07 
Kymera Therapeutics Inc   0.07 
Tourmaline Bio Inc   0.07 
Genenta Science S p a   0.06 
Neumora Therapeutics Inc   0.06 
Krystal Biotech Inc   0.06 
Cullinan Oncology Inc   0.04 
Acumen Pharmaceuticals Inc   0.03 
Cortexyme Inc   0.03 
Vaxcyte Inc   0.03 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com